HC Wainwright



HC Wainwright Recent News

Field Trip Stock Could Climb 300% In One Year
What 3 FibroGen Analysts Are Expecting From Thursday's Roxadustat Adcom Verdict
Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated
Wall Street Analysts See These 4 Stocks As Winners Moving Into December
Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning Judgment
Biotech Stock On The Radar: Nabriva And Its Novel Antibiotic Portfolio
HC Wainwright Hikes Karyopharm Price Target On Accelerated Drug Approval
G1 Therapeutics Investors Recoil, Analysts Bullish In Wake Of Trilaciclib Results
Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?
Viking Has A More Attractive M&A Valuation Than Madrigal, Raymond James Says In Upgrade
Sell-Side Analysts See Upside Potential In Zynerba
HC Wainwright: Celyad's CAR-T Pipeline Has Potential
HC Wainwright: G1 Therapeutics Is Targeting 'Potential Blockbuster' Oncology Markets
Cesca Therapeutics Snags Bullish HC Wainwright Initiation On CAR-T Opportunity
Jounce Therapeutics Stock Slides On Disappointing Data, Wells Fargo Downgrades
HC Wainwright Says Aerpio Pharma Flies Under The Radar Due To OTC Listing, Projects 150% Upside
Analysts See 100% Upside To Rigel After Tavalisse Approval
HC Wainwright: Why The Upside Potential For Palatin Technologies Is Nearly Fivefold
For Eleven Biotherapeutics, Cancer Trial Outcomes Could Be 'Major Catalyst'
Analyst Remains Confident In Corium Despite Bad FDA News
Checkpoint Therapeutics Wins A New Bull As Company's 'Plan Is Quickly Coming Together'
Corium Q4 Sales Top Expectations Ahead Of Slew Of Near-Term Catalysts
H.C. Wainwright: Acadia Is More Than A One-Trick Pony